在具有混合表型的急性白血病中定义了2个生物学和临床上不同的组
Pallavi Galera1, Deepika Dilip2, Andriy Derkach3
1Hematopathology Service Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Blood
|January 15, 2025
概括
混合表型急性髓性白血病 (AML-MP) 和混合表型急性白血病 (MPAL) 是不同的实体. 与MPAL相比,AML-MP表现出较差的治疗反应和独特的遗传特征.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 急性白血病中混合表型 (MP) 存在分类和管理方面的挑战.
- 区分急性髓性白血病与MP (AML-MP) 和MPAL对于有效治疗至关重要.
研究的目的:
- 将AML-MP和MPAL定义为不同的组.
- 描述它们的临床,遗传和转录特征.
- 提供有关病原和治疗的见解.
主要方法:
- 对大量患有MP的急性白血病队伍的分析.
- 临床,遗传和转录组特征的表征.
- 对治疗反应和结果的比较.
主要成果:
- 与MPAL相比,AML-MP对诱导方案的反应较差.
- AML-MP表现出明显的遗传特征,频繁出现RUNX1和TP53突变.
- 转录组分析显示,AML-MP.的茎状丰富和差异化因子的缺陷.
- 与MPAL不同的是,AML-MP很少在治疗后转换为淋巴细胞免疫表型.
结论:
- 应该将AML-MP指定为与MPAL分开的单独诊断.
- 提供了对MP急性白血病的发病和治疗策略的新见解.
- 为未来的研究提出了一个基因组分类框架.
更多相关视频
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
13.9K
10:18From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
13.7K
相关概念视频
01:27Disorders of Leukocytes
844
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
844
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K